Citation only
via Europe PMC
Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling.
Yao C, Cai Z, Song H, Xue Q, Cai B, He W, Kong X, Yang T, Jin J, Li J, Chen B, Zhao F, Chen J, Liu J.
Pharmacological research · 2026
Abstract
The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens suggested greater macrophage-associated polyol-pathway activity in the osteoporosis specimen. In primary bone marrow-derived macrophages, silencing of Akr1b3 and Sord produced opposing effects on osteoclast differentiation. Epalrestat suppressed RANKL-induced osteoclastogenesis and attenuated bone loss in diabetic, ovariectomy-induced, and inflammatory mouse models under early-intervention regimens. Mechanistic analyses showed improved NADPH/NADP⁺ and GSH/GSSG balance, reduced oxidative stress, and attenuated cytosolic and mitochondrial Ca²⁺ signals and Ca²⁺ oscillations. Genetic and osmotic-compensation experiments further supported a model in which intracellular sorbitol contributes to the osmotic regulation of Ca²⁺ oscillations. Additional findings included reduced inflammation in osteolysis and arthritis models, altered macrophage polarization, and partial preservation of bone marrow vascular features. Together, these findings connect glucose metabolism with redox and Ca²⁺ regulation during osteoclast differentiation and provide a rationale for further evaluation of epalrestat in skeletal disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1016/j.phrs.2026.109698
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
C, Y., Z, C., H, S., Q, X., B, C., W, H., X, K., T, Y., J, J., J, L., B, C., F, Z., J, C., & J., L. (2026). Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. <em>Pharmacological research</em>. https://doi.org/10.1016/j.phrs.2026.109698
Vancouver
C Y, Z C, H S, Q X, B C, W H, et al. Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling. Pharmacological research. 2026. doi:10.1016/j.phrs.2026.109698.
BibTeX
@article{yao2026Polyol,
title = {Polyol pathway inhibition by epalrestat attenuates pathological bone loss through redox homeostasis and sorbitol-linked calcium signaling.},
author = {Yao C and Cai Z and Song H and Xue Q and Cai B and He W and Kong X and Yang T and Jin J and Li J and Chen B and Zhao F and Chen J and Liu J.},
journal = {Pharmacological research},
year = {2026},
doi = {10.1016/j.phrs.2026.109698},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Elsevier eBooks 2021
Citation only
Osteoporosis and bone loss
2014
Citation only
Bone loss in osteoporosis and rheumatoid arthritis diseases: The effects of disease mechanisms, age, gender and ethnic origin on responsiveness to treatment.
Advanced Science 2026
Open access · CC-BY
Atrophic Skeletal Muscle‐Derived Extracellular Vesicles Transfer miR‐125a‐5p to Inhibit Bone Formation in Osteoporosis during Aging
Endocrinology and Metabolism Clinics of North America 2005
Citation only
Pathophysiology of Age-Related Bone Loss and Osteoporosis
Springer eBooks 2003
Citation only
Techniques for the Investigation of Age-Related Bone Loss and Osteoporosis in Archaeological Bone
Nutrients 2026
Open access · OA